<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02370784</url>
  </required_header>
  <id_info>
    <org_study_id>PRO14010170</org_study_id>
    <secondary_id>1R21AR066305-01A1</secondary_id>
    <nct_id>NCT02370784</nct_id>
  </id_info>
  <brief_title>Atorvastatin for Microvascular Endothelial Function and Raynaud in Early Diffuse Scleroderma</brief_title>
  <acronym>TAMER</acronym>
  <official_title>The Effect of Atorvastatin on Microvascular Endothelial Function and Raynaud in Early Diffuse Systemic Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Robyn T. Domsic, MD, MPH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn about the effect atorvastatin on blood vessel function&#xD;
      and Raynaud symptoms in patients with early diffuse systemic sclerosis.&#xD;
&#xD;
      Systemic sclerosis is a disease characterized by blood vessel injury, immune system&#xD;
      activation and fibrosis. Blood vessel injury is thought to be important early in the disease.&#xD;
      Blood vessel complications of systemic sclerosis include Raynaud phenomena, finger and toe&#xD;
      ulcers, and pulmonary hypertension. While atorvastatin reduces cholesterol, it is recognized&#xD;
      to have many effects beyond cholesterol reduction. These include improvement of blood vessel&#xD;
      function and reduction of fibrosis. We hypothesize that treatment with atorvastatin over 16&#xD;
      weeks will improve blood vessel function and Raynaud symptom in patients with early diffuse&#xD;
      systemic sclerosis. We hope that by targeting therapy early in the disease we may delay blood&#xD;
      vessel changes and improve Raynaud symptoms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Systemic sclerosis (SSc) is a multisystem autoimmune illness characterized by vasculopathy,&#xD;
      immune system activation and fibrosis of the skin and internal organs. SSc affects&#xD;
      approximately 240 people per million in the US, but is a disease for which there is no FDA&#xD;
      approved medication. Current hypothesis of pathogenesis suggest that a vascular injury with&#xD;
      endothelial dysfunction may be an inciting event contributing to immunologic activation and&#xD;
      fibrosis in the pathogenesis of the disease. More than 90% of individuals with SSc have&#xD;
      vascular complications including Raynaud phenomenon, digital ulcers or gangrene and pulmonary&#xD;
      hypertension; with microvascular abnormalities felt to contribute to Raynaud and digital&#xD;
      ulcerations.&#xD;
&#xD;
      Statin medications are well-recognized to have pleiotropic effects which may modify all three&#xD;
      aspects of SSc pathogenesis. Early diagnosis and treatment of microvascular endothelial&#xD;
      dysfunction and Raynaud phenomeonan may have the greatest effect in early disease. Thus, we&#xD;
      hypothesize that treatment with atorvastatin in a well-defined cohort of early diffuse&#xD;
      systemic sclerosis will produce beneficial results.&#xD;
&#xD;
      Participants will be patients with early diffuse systemic sclerosis and Raynaud phenomenon&#xD;
      who have no history of cardiovascular disease or diabetes. A total of 30 patients will be&#xD;
      enrolled and followed for 16 weeks. Half the patients will be randomized to atorvastatin and&#xD;
      half to placebo. Patients will be allowed to continue underlying immunosuppressive and&#xD;
      Raynaud therapy at stable doses during the trial. Since this is a pilot study, future larger&#xD;
      controlled trials will be necessary to clearly demonstrate drug effectiveness. Investigators&#xD;
      are hoping that this study will give us signals to guide a future multicenter clinical trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">December 15, 2019</completion_date>
  <primary_completion_date type="Actual">December 15, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Patients Improving Their EndoPAT Reactive Hyperemia Index (RHI) at the End-of-study (16 Weeks)</measure>
    <time_frame>Change in RHI from baseline to 16 weeks expressed as the percentage of patients who improve (respond).</time_frame>
    <description>EndoPAT is a proprietary device that assesses digital (microvascular) endothelial function during reactive hyperemia. A probe is placed on both index fingers. After 5 minutes of baseline observation, one arm is occluded for 5 minutes, while the other is not and serves as control. Output is the reactive hyperemia index (RHI), calculated as the post-to-pre occlusion signal ratio in the occluded side, &quot;normalized to the control side and further corrected for baseline vascular tone&quot; per Itamar Medical. There are no units. RHI ≤ 1.67 is abnormal and indicates endothelial dysfunction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the Raynaud Condition Score (RCS) at 16 Weeks (End-of-study) From Baseline</measure>
    <time_frame>change in RCS from baseline to week 16</time_frame>
    <description>The Raynaud Condition Score is a patient-reported outcome of a single question regarding Raynaud severity. It is a visual analog scale with a results range of 0-100. A score of 0 us is no symptoms, and 100 severe symptoms. It is recommended by OMERACT for assessment of Raynaud phenomenon.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Median Change in the Raynaud Phenomenon Visual Analog Scale (RP-VAS) Score at 16 Weeks (End-of-study) Compared to Baseline in the Atorvastatin and Placebo Groups.</measure>
    <time_frame>baseline to 16 weeks</time_frame>
    <description>The RP-VAS scale measure ranges from 0-100, with 0 being no symptoms and 100 severe symptoms. Reported is the median and interquartile range of change between baseline and week 16 (end-of-study).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% of Patients Who Improved Their Brachial Flow-mediation Dilation (%FMD) at 16 Weeks</measure>
    <time_frame>baseline to 16 weeks</time_frame>
    <description>%FMD = change in brachial artery flow-mediation dilation between pre and post-ischemia. Baseline (pre-ischemia) is the reference to which percentage change is calculated.&#xD;
Result is expressed as the % of patients who had an improvement in their %FMD at 16 weeks compared to baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Scleroderma</condition>
  <arm_group>
    <arm_group_label>Active Drug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>atorvastatin 40 mg once daily for sixteen weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>receive a placebo of similar appearance once daily for sixteen weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atorvastatin</intervention_name>
    <description>Atorvastatin is an oral cholesterol-lowering medication commonly referred to as statin therapy.</description>
    <arm_group_label>Active Drug</arm_group_label>
    <other_name>Lipitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral drug of similar appearance to atorvastatin</description>
    <arm_group_label>Placebo control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. early diffuse scleroderma (&lt; 3 years from the first scleroderma-related symptom)&#xD;
&#xD;
          2. Raynaud phenomenon&#xD;
&#xD;
          3. no use of lipid-lowering medication within 60 days&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. pregnancy&#xD;
&#xD;
          2. renal or kidney dysfunction (creatinine &lt; 2.0 mg/dL or creatinine clearance &lt; 60&#xD;
             c/min)&#xD;
&#xD;
          3. diabetes mellitus&#xD;
&#xD;
          4. known cardiovascular disease or a prior history of stroke&#xD;
&#xD;
          5. history of liver disease&#xD;
&#xD;
          6. new or changed dose of calcium channel blockers (CCB) and angiotensin receptor&#xD;
             blockers (ARBs) in the last 4 weeks&#xD;
&#xD;
          7. known allergy or adverse reaction to the atorvastatin or another statin drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15261</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>January 26, 2015</study_first_submitted>
  <study_first_submitted_qc>February 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2015</study_first_posted>
  <results_first_submitted>December 14, 2019</results_first_submitted>
  <results_first_submitted_qc>August 10, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 12, 2020</results_first_posted>
  <last_update_submitted>August 10, 2020</last_update_submitted>
  <last_update_submitted_qc>August 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Robyn T. Domsic, MD, MPH</investigator_full_name>
    <investigator_title>MD, MPH</investigator_title>
  </responsible_party>
  <keyword>early diffuse scleroderma</keyword>
  <keyword>Raynaud</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 13, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/84/NCT02370784/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited at a single Scleroderma Center between March 2015 and August 2017.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Atorvastatin 40 mg Daily</title>
          <description>Length of intervention: 16 weeks atorvastatin: Atorvastatin is an oral cholesterol-lowering medication commonly referred to as statin therapy.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Control</title>
          <description>Placebo: oral drug of similar appearance to atorvastatin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Patient started prohibited medication</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Atorvastatin 40 mg Daily</title>
          <description>Atorvastatin 40 mg daily x 16 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo daily x 16 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.0" spread="13.9"/>
                    <measurement group_id="B2" value="55.7" spread="5.3"/>
                    <measurement group_id="B3" value="53.3" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White, non-hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African-American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of hyperlipidemia</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of hypertension</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Obesity</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Family history of early cardiovascular disease</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>mean modified Rodnan skin score</title>
          <description>The modified Rodnan skin score (mRSS) measures skin thickness in 17 body areas. Each area is scored from 0 (no thickness) to 3 (bound down), and then summed. The mRSS range is 0-51. 0 is normal, and indicative of no skin thickening. Higher scores indicate greater skin thickening.</description>
          <units>points</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.9" spread="9.6"/>
                    <measurement group_id="B2" value="22.8" spread="8.9"/>
                    <measurement group_id="B3" value="21.3" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean EndoPAT reactive hyperemia index (RHI)</title>
          <description>RHI ≤ 1.67 is abnormal and indicates endothelial dysfunction. A score of 1.67 or above suggests normal endothelial function. Results are presented as mean RHI +/- standard deviation.</description>
          <units>units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.36" spread="0.36"/>
                    <measurement group_id="B2" value="1.85" spread="1.20"/>
                    <measurement group_id="B3" value="1.46" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Raynaud condition score (median, IQR)</title>
          <description>The RCS is a self-assessment of Raynaud phenomenon activity using a 0-10 ordinal scale. Patients are asked to &quot;please rate the difficulty you had today with your Raynaud condition by circling the appropriate number below&quot;. 0 indicates no difficulty, and 10 the most difficulty.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.0" lower_limit="3.0" upper_limit="7.5"/>
                    <measurement group_id="B2" value="2.0" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="B3" value="2.5" lower_limit="1.0" upper_limit="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Raynaud symptom severity assessed by visual analog scale</title>
          <description>This is a visual analog scale that is measured from 0-15 cm. 0 corresponds to no activity/severity, and 15 to the highest level.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.0" lower_limit="2.0" upper_limit="7.5"/>
                    <measurement group_id="B2" value="1.5" lower_limit="0.5" upper_limit="3.0"/>
                    <measurement group_id="B3" value="2.3" lower_limit="1.0" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Brachial % flow mediated dilation (%FMD)</title>
          <units>%</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.3" lower_limit="7.4" upper_limit="14.7"/>
                    <measurement group_id="B2" value="10.3" lower_limit="7.1" upper_limit="13.2"/>
                    <measurement group_id="B3" value="10.3" lower_limit="7.3" upper_limit="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Patients Improving Their EndoPAT Reactive Hyperemia Index (RHI) at the End-of-study (16 Weeks)</title>
        <description>EndoPAT is a proprietary device that assesses digital (microvascular) endothelial function during reactive hyperemia. A probe is placed on both index fingers. After 5 minutes of baseline observation, one arm is occluded for 5 minutes, while the other is not and serves as control. Output is the reactive hyperemia index (RHI), calculated as the post-to-pre occlusion signal ratio in the occluded side, &quot;normalized to the control side and further corrected for baseline vascular tone&quot; per Itamar Medical. There are no units. RHI ≤ 1.67 is abnormal and indicates endothelial dysfunction.</description>
        <time_frame>Change in RHI from baseline to 16 weeks expressed as the percentage of patients who improve (respond).</time_frame>
        <population>The patient who did not complete the study had his data analyzed using last observation carried forward. Improvement was defined as an increase in the RHI from baseline to 16 weeks. Non-responders were defined as no change or worsening (decrease) in the RHI at 16 weeks. Results are expressed as a percentage</population>
        <group_list>
          <group group_id="O1">
            <title>Active Drug</title>
            <description>atorvastatin 40 mg once daily for sixteen weeks&#xD;
atorvastatin: Atorvastatin is an oral cholesterol-lowering medication commonly referred to as statin therapy.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Control</title>
            <description>receive a placebo of similar appearance once daily for sixteen weeks&#xD;
Placebo: oral drug of similar appearance to atorvastatin</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Improving Their EndoPAT Reactive Hyperemia Index (RHI) at the End-of-study (16 Weeks)</title>
          <description>EndoPAT is a proprietary device that assesses digital (microvascular) endothelial function during reactive hyperemia. A probe is placed on both index fingers. After 5 minutes of baseline observation, one arm is occluded for 5 minutes, while the other is not and serves as control. Output is the reactive hyperemia index (RHI), calculated as the post-to-pre occlusion signal ratio in the occluded side, &quot;normalized to the control side and further corrected for baseline vascular tone&quot; per Itamar Medical. There are no units. RHI ≤ 1.67 is abnormal and indicates endothelial dysfunction.</description>
          <population>The patient who did not complete the study had his data analyzed using last observation carried forward. Improvement was defined as an increase in the RHI from baseline to 16 weeks. Non-responders were defined as no change or worsening (decrease) in the RHI at 16 weeks. Results are expressed as a percentage</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Raynaud Condition Score (RCS) at 16 Weeks (End-of-study) From Baseline</title>
        <description>The Raynaud Condition Score is a patient-reported outcome of a single question regarding Raynaud severity. It is a visual analog scale with a results range of 0-100. A score of 0 us is no symptoms, and 100 severe symptoms. It is recommended by OMERACT for assessment of Raynaud phenomenon.</description>
        <time_frame>change in RCS from baseline to week 16</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Drug</title>
            <description>atorvastatin 40 mg once daily for sixteen weeks&#xD;
atorvastatin: Atorvastatin is an oral cholesterol-lowering medication commonly referred to as statin therapy.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Control</title>
            <description>receive a placebo of similar appearance once daily for sixteen weeks&#xD;
Placebo: oral drug of similar appearance to atorvastatin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Raynaud Condition Score (RCS) at 16 Weeks (End-of-study) From Baseline</title>
          <description>The Raynaud Condition Score is a patient-reported outcome of a single question regarding Raynaud severity. It is a visual analog scale with a results range of 0-100. A score of 0 us is no symptoms, and 100 severe symptoms. It is recommended by OMERACT for assessment of Raynaud phenomenon.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" lower_limit="-2.0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="-1.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Median Change in the Raynaud Phenomenon Visual Analog Scale (RP-VAS) Score at 16 Weeks (End-of-study) Compared to Baseline in the Atorvastatin and Placebo Groups.</title>
        <description>The RP-VAS scale measure ranges from 0-100, with 0 being no symptoms and 100 severe symptoms. Reported is the median and interquartile range of change between baseline and week 16 (end-of-study).</description>
        <time_frame>baseline to 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Drug</title>
            <description>atorvastatin 40 mg once daily for sixteen weeks&#xD;
atorvastatin: Atorvastatin is an oral cholesterol-lowering medication commonly referred to as statin therapy.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Control</title>
            <description>receive a placebo of similar appearance once daily for sixteen weeks&#xD;
Placebo: oral drug of similar appearance to atorvastatin</description>
          </group>
        </group_list>
        <measure>
          <title>The Median Change in the Raynaud Phenomenon Visual Analog Scale (RP-VAS) Score at 16 Weeks (End-of-study) Compared to Baseline in the Atorvastatin and Placebo Groups.</title>
          <description>The RP-VAS scale measure ranges from 0-100, with 0 being no symptoms and 100 severe symptoms. Reported is the median and interquartile range of change between baseline and week 16 (end-of-study).</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="-1.5" upper_limit="6.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-1.0" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>% of Patients Who Improved Their Brachial Flow-mediation Dilation (%FMD) at 16 Weeks</title>
        <description>%FMD = change in brachial artery flow-mediation dilation between pre and post-ischemia. Baseline (pre-ischemia) is the reference to which percentage change is calculated.&#xD;
Result is expressed as the % of patients who had an improvement in their %FMD at 16 weeks compared to baseline.</description>
        <time_frame>baseline to 16 weeks</time_frame>
        <population>For the patient with a SAE, data was treated as last observation carried forward</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin 40 mg Daily</title>
            <description>Atorvastatin 40 mg daily x 16 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo daily x 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>% of Patients Who Improved Their Brachial Flow-mediation Dilation (%FMD) at 16 Weeks</title>
          <description>%FMD = change in brachial artery flow-mediation dilation between pre and post-ischemia. Baseline (pre-ischemia) is the reference to which percentage change is calculated.&#xD;
Result is expressed as the % of patients who had an improvement in their %FMD at 16 weeks compared to baseline.</description>
          <population>For the patient with a SAE, data was treated as last observation carried forward</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>16 weeks plus 30 days after the end of intervention</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Atorvastatin 40 mg Daily</title>
          <description>Length of intervention: 16 weeks atorvastatin: Atorvastatin is an oral cholesterol-lowering medication commonly referred to as statin therapy.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Control</title>
          <description>Placebo: oral drug of similar appearance to atorvastatin</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Esophageal cancer</sub_title>
                <description>Patient was diagnosed shortly before the end of the intervention period with esophageal cancer and pulmonary hypertension requiring vasodilators, which were prohibited in the protocol. The patient was withdrawn from the study.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This was a single-centered trial, and underpowered, as only 24 were enrolled with an initial goal of 30.&#xD;
The groups were unbalanced for both the primary and secondary endpoint at baseline despite randomization.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Robyn T. Domsic, MD MPH</name_or_title>
      <organization>University of Pittsburgh School of Medicine</organization>
      <phone>412-383-8000</phone>
      <email>rtd4@pitt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

